Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Innoviva Inc (NQ: INVA )

19.36 +0.10 (+0.52%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Innoviva Inc

< Previous 1 2 3 4 Next >
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
From Innoviva, Inc.
Via Business Wire
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
5 Value Stocks In The Healthcare Sector
Via Benzinga
Innoviva Announces Retirement of Board Chairman
From Innoviva, Inc.
Via Business Wire
FDA's AdComm Panel Favors Innoviva's Drug For Multidrug-Resistant Bacterial Infections
Via Benzinga
What 4 Analyst Ratings Have To Say About Innoviva
Via Benzinga
Elon Musk Says US Intel Agencies Had Access To Twitter DMs, Alibaba's Ant IPO Might Actually See Light, Airbus Pushes Some 2024 Deliveries: Today's Top Stories
Benzinga Elon Musk Drops Bombshell: US Intel Agencies Were Reading Your Twitter DMs 
Via Benzinga
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
From Innoviva, Inc.
Via Business Wire
Innoviva Stock Trading Halted Today
From Innoviva, Inc.
Via Business Wire
Innoviva Earnings Perspective: Return On Capital Employed
Via Benzinga
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
From Innoviva, Inc.
Via Business Wire
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Four Undervalued Healthcare Stocks for 2023
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc. 
Via MarketBeat
Exposures COVID-19
Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
From Innoviva, Inc.
Via Business Wire
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022
--- Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological Endpoints 
From Entasis Therapeutics Holdings Inc.
Via GlobeNewswire
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022
Six abstracts selected for presentation, including three oral presentations 
From Entasis Therapeutics Holdings Inc.
Via GlobeNewswire
A Look Into Healthcare Sector Value Stocks
The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base... 
Via Benzinga
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings
Via Benzinga
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators... 
Via Benzinga
Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
3 No-Brainer Stocks Under $10 to Buy for September
Cash-rich investors have the flexibility to buy no-brainer penny stocks to boost overall returns in a risk-adverse environment. 
Via InvestorPlace
Innoviva Completes Acquisition of La Jolla Pharmaceutical
From Innoviva, Inc.
Via Business Wire
Innoviva's Return On Capital Employed Overview
Pulled from Benzinga Pro data, Innoviva (NASDAQ:INVA) showed a loss in earnings since Q1, totaling $21.37 million. Sales, on the other hand, increased by 20.17% to $108.22 million during Q2. 
Via Benzinga
Innoviva: Q2 Earnings Insights
Innoviva (NASDAQ:INVA) reported its Q2 earnings results on Wednesday, July 27, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Innoviva missed estimated earnings... 
Via Benzinga
Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 108 companies set new 52-week lows. 
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
What is a Value Stock? 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.